Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-06
2007-11-06
Solola, Taofiq (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S210010, C544S107000, C548S557000, C564S139000
Reexamination Certificate
active
10837179
ABSTRACT:
The present application describes modulators of MCP-1 of formula (I):or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
REFERENCES:
patent: 5700801 (1997-12-01), Pieper et al.
patent: 6011052 (2000-01-01), Padia et al.
patent: 6706712 (2004-03-01), Cherney
patent: 2003/0060459 (2003-03-01), Carter et al.
patent: 2003/0216434 (2003-11-01), Cherney
patent: 2004/0110736 (2004-06-01), Cherney
patent: 2004/0186143 (2004-09-01), Carter et al.
patent: 2004/0235835 (2004-11-01), Carter
patent: 2005/0043392 (2005-02-01), Carter
patent: 19607436 (1997-04-01), None
patent: 686629 (1995-12-01), None
patent: 2003183286 (2003-07-01), None
patent: WO97/44329 (1997-11-01), None
patent: WO98/06703 (1998-02-01), None
patent: WO99/07351 (1999-02-01), None
patent: WO99/07678 (1999-02-01), None
patent: WO99/25686 (1999-05-01), None
patent: WO99/40913 (1999-08-01), None
patent: WO99/40914 (1999-08-01), None
patent: WO99/46991 (1999-09-01), None
patent: WO 00/46196 (2000-08-01), None
patent: WO 00/69815 (2000-11-01), None
patent: WO 00/69820 (2000-11-01), None
patent: WO 01/74774 (2001-11-01), None
patent: WO 02/50019 (2002-06-01), None
patent: WO 02/060859 (2002-08-01), None
patent: WO 02/070523 (2002-09-01), None
patent: WO 02/074738 (2003-02-01), None
patent: WO 03/016302 (2003-02-01), None
patent: WO03022799 (2003-03-01), None
patent: WO 03075853 (2003-09-01), None
patent: WO 2004/005248 (2004-01-01), None
patent: WO 2004071449 (2004-08-01), None
patent: WO 2004071460 (2004-08-01), None
patent: WO 2004098512 (2004-11-01), None
Forbes, I.T. et al., “CCR2B Receptor Antagonists: Conversion of a Weak HTS Hit to a Potent Lead Compound”, Bioorganic & Medicinal Chemistry Letters, vol. 10, pp. 1803-1806 (2000).
Mirzadegan, T. et al., “Identification of the Binding Site for a Novel Class of CCR2b Chemokine Receptor Antagonists”, The Journal of Biological Chemistry, vol. 275, No. 33, pp. 25562-25571 (2000).
Baba, M. et al., “A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity”, Proc. Natl. Acad. Sci. USA, vol. 96, pp. 5698-5703 (1999).
U.S. Appl. No. 10/776,828, filed Feb. 11, 2004.
U.S. Appl. No. 10/776,586, filed Feb. 11, 2004.
U.S. Appl. No. 10/836,032, filed Apr. 29, 2004.
U.S. Appl. No. 10/922,406, Carter et al., filed Aug. 19, 2004.
U.S. Appl. No. 10/923,619, Carter et al., filed Aug. 19, 2004.
U.S. Appl. No. 10/923,538, Carter et al., filed Aug. 19, 2004.
Bristol--Myers Squibb Company
Duncan Laurelee A.
Solola Taofiq
VanAtten Mary K.
LandOfFree
Cyclic derivatives as modulators of chemokine receptor activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic derivatives as modulators of chemokine receptor activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic derivatives as modulators of chemokine receptor activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3832224